MedImmune To Add 38 Ethyol Reps Following Product Reacquisition
MedImmune will add 38 oncology reps to promote Ethyol (amifostine) following reacquisition of U.S. rights for the cytoprotective agent from Alza.
You may also be interested in...
MedImmune's acquisition of U.S. Bioscience will likely lead to a tighter relationship with Abbott. Abbott already co-markets MedImmune's Synagis (palivizumab) and is in the process of acquiring Alza, which co-promotes U.S. Bioscience's top product Ethyol (amifostine) in the U.S.
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials